{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:43:48Z","timestamp":1761007428729,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Acute leukemias (AL) in children under 1-year-old are combined under the term \u201cinfant leukemia\u201d and are a very rare malignancies, accounting for up to 5% of all childhood AL cases. The predominance of unfavorable clinical and laboratory characteristics leads to unsatisfactory treatment results, even with the use of modern treatment protocols. Patients\/Methods: A comprehensive search through MEDLINE, PubMed, Scopus, and ScienceDirect using infant leukemia-related keywords was performed and included a final set of 52 academic articles. Our own experience included 11 patients with infant leukemia underwent allo-HSCT (allogeneic hematopoietic stem cell transplantation) at the NN Blokhin National Medical Research Center of Oncology in 2021\u20132023. Types of leukemia included acute myeloid leukemia, lymphoblastic leukemia, and mixed-phenotype acute leukemia. The most frequent cytogenetic aberration was KMT2A. All patients were in clinical and hematological remission, but four had positive MRD status (minimal residual disease). Donors: haploidentical\u20145 (45.4%), matched unrelated donor\u20145 (45.4%), and matched related donor\u20141 (9.2%). Graft manipulations: post-transplant cyclophosphamide was given to three patients with haplo-HSCT, and TCR\u03b1\u03b2\/CD19 depletion was performed in two patients. The type of immunosuppressive therapy (IST) varied based on the donor. Conditioning regimens were myeloablative. Results: Median follow-up was 23.5 months. Acute GVHD grade I\u2013II developed in two patients (18%) and grade III\u2013IV in three patients (27%). The overall survival rate was 54.5% (n = 6). The relapse rate after allo-HSCT was 18% (n = 2). The most common cause of treatment failure was infectious complications in the early post-transplant period (70%). Conclusions: Our center\u2019s experience demonstrated acceptable transplant-related mortality and satisfactory relapse rates after allo-HSCT in patients with infant leukemia. The treatment of acute leukemia in infants is challenging, and optimal protocols are being developed around the world specifically for these patients. Taking into account the characteristics of this age group, the choice of chemotherapy drug doses should be carefully considered, and the indications for allo-HSCT should be balanced.<\/jats:p>","DOI":"10.3390\/children12101418","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:27:29Z","timestamp":1760963249000},"page":"1418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for Infant Leukemia: A Single-Center Case Series and Narrative Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-2479","authenticated-orcid":false,"given":"Irina","family":"Kostareva","sequence":"first","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirill","family":"Kirgizov","sequence":"additional","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-3158","authenticated-orcid":false,"given":"Irina","family":"Shubina","sequence":"additional","affiliation":[{"name":"Research Institute of Experimental Diagnostics and Therapy of Tumors, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nara","family":"Stepanyan","sequence":"additional","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Batmanova","sequence":"additional","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-2365","authenticated-orcid":false,"given":"Timur","family":"Valiev","sequence":"additional","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihail","family":"Kiselevsky","sequence":"additional","affiliation":[{"name":"Research Institute of Experimental Diagnostics and Therapy of Tumors, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Varfolomeeva","sequence":"additional","affiliation":[{"name":"Research Institute of Pediatric Oncology and Hematology, FSBI \u201cN.N. Blokhin National Medical Research Center of Oncology\u201d of the Ministry of Health of Russia, Kashirskoye sh. 24, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.24287\/1726-1708-2018-17-2-21-27","article-title":"Results of allogeneic hematopoietic stem cell transplantation from haploidentical donors in children and adolescents with high-risk acute leukemia using unmanipulated graft. Ten years experience of R.G. Memorial institute of children oncology, hematology and transplantation","volume":"17","author":"Paina","year":"2018","journal-title":"Pediatr. Hematol.\/Oncol. Immunopathol."},{"key":"ref_2","first-page":"372","article-title":"Infant leukemia biology, aetiology and treatment","volume":"10","author":"Greaves","year":"1996","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"dmm049189","DOI":"10.1242\/dmm.049189","article-title":"Infant leukaemia\u2014Faithful models, cell of origin and the niche","volume":"14","author":"Duguid","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cll.2021.04.002","article-title":"Infant Acute Leukemia","volume":"41","author":"Wertheim","year":"2021","journal-title":"Clin. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"G\u00f3recki, M., Kozio\u0142, I., Kopystecka, A., Budzy\u0144ska, J., Zawitkowska, J., and Lejman, M. (2023). Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030821"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kulczycka, M., Derlatka, K., Tasior, J., Sygacz, M., Lejman, M., and Zawitkowska, J. (2024). Infant Acute Lymphoblastic Leukemia\u2014New Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073721"},{"key":"ref_7","unstructured":"Li, W. (2022). Chapter 2\u2014Infant Leukemia. Leukemia [Internet], Exon Publications."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-021-01021-1","article-title":"Acute Leukemia in Infants","volume":"23","author":"Ibrahimova","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-009-0023-4","article-title":"Infant acute lymphoblastic leukemia: Lessons learned and future directions","volume":"4","author":"Pieters","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00043426-199801000-00001","article-title":"Molecular genetics of childhood leukemias","volume":"20","author":"Rubnitz","year":"1998","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Winters, A.C., and Bernt, K.M. (2017). MLL-rearranged leukemias\u2014An update on science and clinical approaches. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00004"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"B\u00fcchner, T., Hiddemann, W., W\u00f6rmann, B., Schellong, G., Ritter, J., and Creutzig, U. (2001). Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk MDS. Acute Leukemias VIII. Haematology and Blood Transfusion\/H\u00e4matologie und Bluttransfusion, Springer.","DOI":"10.1007\/978-3-642-18156-6"},{"key":"ref_14","first-page":"677","article-title":"Clinical and experimental studies of childhood acute myeloid leukemia with 11q23\/MLL rearrangements","volume":"29","author":"He","year":"2012","journal-title":"Chin. J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41375-018-0353-0","article-title":"NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia","volume":"33","author":"Molina","year":"2019","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yao, J., Li, G., Cui, Z., Chen, P., Wang, J., Hu, Z., Zhang, L., and Wei, L. (2022). The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.876076"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/1042819031000063363","article-title":"Recent advances in the treatment of infant acute myeloid leukemia","volume":"44","author":"Ishii","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/ol.2020.11583","article-title":"Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments","volume":"20","author":"Huang","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.25322","article-title":"Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)","volume":"62","author":"Dreyer","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_23","first-page":"2010","article-title":"Pediatric Oncology Group (POG) studies 8493 and 8821: Therapy for infants with acute myeloid leukemia\u2014A report from the Children\u2019s Cancer Group","volume":"88","author":"Ravindranath","year":"1996","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1038\/bcj.2014.17","article-title":"The evolution of clinical trials for infant acute lymphoblastic leukemia","volume":"4","author":"Kotecha","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","article-title":"Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98","volume":"22","author":"Creutzig","year":"2004","journal-title":"JCO"},{"key":"ref_26","first-page":"150","article-title":"Recent advance in treatment of childhood acute lymphoblastic leukemia","volume":"34","author":"Watanabe","year":"2007","journal-title":"Gan to Kagaku Ryoho"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children\u2019s Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e28692","DOI":"10.1002\/pbc.28692","article-title":"Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG)","volume":"67","author":"Hasegawa","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomized trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(05)66998-X","article-title":"Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomization in an international prospective study","volume":"366","author":"Balduzzi","year":"2005","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood.V95.8.2729","article-title":"Treatment outcome in infant acute lymphoblastic leukemia","volume":"95","author":"Ferster","year":"2000","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2141.2002.03442.x","article-title":"Treatment of infants with lymphoblastic leukaemia: Results of the UK Infant Protocols 1987\u20131999","volume":"1172","author":"Chessells","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2022008548","article-title":"Lacorazza HD. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia","volume":"7","author":"Bridges","year":"2023","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2000.18.18.3256","article-title":"High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support","volume":"18","author":"Marco","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood-2004-04-1390","article-title":"Infant acute lymphoblastic leukemia with MLL gene rearrangements: Outcome following intensive chemotherapy and hematopoietic stem cell transplantation","volume":"104","author":"Kosaka","year":"2004","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2004-08-3312","article-title":"Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia","volume":"105","author":"Sanders","year":"2005","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/jco.2007.25.18_suppl.9514","article-title":"Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia","volume":"25","author":"Dreyer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_39","first-page":"197","article-title":"Infant acute lymphoblastic leukemia: A 20-year children\u2019s hospital experience. Fetal Pediatr","volume":"27","author":"Murray","year":"2008","journal-title":"Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2011.267","article-title":"Favorable outcome in infants with AML after intensive first- and second-line treatment: An AML-BFM study group report","volume":"26","author":"Creutzig","year":"2012","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated with the Interfant-06 Pro-tocol: Results From an International Phase III Randomized Study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e190081","DOI":"10.1001\/jamapediatrics.2019.0081","article-title":"Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant","volume":"173","author":"Parikh","year":"2019","journal-title":"JAMA Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V98.13.3589","article-title":"Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: Results of the Japan Infant Leukemia Study Group","volume":"98","author":"Kawasaki","year":"2001","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/bloodadvances.2020004157","article-title":"Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia","volume":"5","author":"Takachi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbmt.2005.08.031","article-title":"Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"11","author":"Jacobsohn","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wang, Y., Guo, Y., Ling, X., Li, J., Hu, T., Zhang, Z., Hu, M., Song, Z., Yue, M., and Tang, R. (2025). Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-05602-z"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/bbmt.2001.v7.pm11302549","article-title":"Secondary failure of platelet recovery after hematopoietic stem cell transplantation","volume":"7","author":"Bruno","year":"2001","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_48","first-page":"421723","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk. Res. Treat."},{"key":"ref_49","first-page":"114","article-title":"Graft failure in allogeneic hematopoietic stem cell recipients:diagnosis and treatment. Bulletin of the Medical Institute \u201cREAVIZ\u201d","volume":"13","author":"Maslikova","year":"2023","journal-title":"Rehabiltation Dr. Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbmt.2008.10.015","article-title":"Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia","volume":"15","author":"Hunger","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e28739","DOI":"10.1002\/pbc.28739","article-title":"Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia","volume":"68","author":"Moskop","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/leu.2014.172","article-title":"Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia","volume":"29","author":"Koh","year":"2015","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/asheducation-2013.1.601","article-title":"Does hematopoietic stem cell transplantation benefit infants with acute leukemia?","volume":"2013","author":"Sison","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2019-131447","article-title":"Clinical experience of CAR T cell immunotherapy for relapsed and refractory infant ALL demonstrates feasibility and favorable responses","volume":"134","author":"Annesley","year":"2019","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPH.0000000000001857","article-title":"Use of CD19-directed CAR T-cell therapy in an infant with refractory acute lymphoblastic leukemia","volume":"43","author":"Breese","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Diesch-Furlanetto, T., Gabriel, M., Zajac-Spychala, O., Cattoni, A., Hoeben, B.A.W., and Balduzzi, A. (2021). Late Effects After Haema-topoietic Stem Cell Transplantation in ALL, Long-Term Follow-Up and Transition: A Step Into Adult Life. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.773895"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12185-019-02684-0","article-title":"Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia","volume":"110","author":"Takachi","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MPH.0000000000002065","article-title":"Potential Use of Mesenchymal Multipotent Cells for Hemopoietic Stem Cell Transplantation: Pro and Contra","volume":"43","author":"Kiselevskiy","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_60","first-page":"194","article-title":"Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis","volume":"79","author":"Poonsombudlert","year":"2020","journal-title":"Hawaii J. Health Soc. Welf."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/10\/1418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:16:52Z","timestamp":1760966212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/10\/1418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["children12101418"],"URL":"https:\/\/doi.org\/10.3390\/children12101418","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}